V116 is an investigational, 21-valent pneumococcal conjugate vaccine specifically designed to protect adults
Receives registration of Valganciclovir powder for oral solution in Germany
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
General Medicine grows 5% and Vaccines 10% led by Shingrix
PhytoSquene now available for clinical and commercial use
Lack of technology transfer stands out as a formidable barrier
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Subscribe To Our Newsletter & Stay Updated
